Overview
- Thursday's case report from a German team detailed a 47-year-old with autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome who entered drug-free remission after one CD19 CAR‑T treatment.
- The engineered cells cleared CD19‑positive B cells that make autoantibodies, ending daily transfusions within a week and normalizing hemoglobin by day 25 as clot‑risk antibodies fell to undetectable levels for about 11 months.
- A pediatric series presented by Italian clinicians reported short- to mid-term drug-free remissions in several of eight children given the same CD19 approach, with only low‑grade cytokine and neurotoxicity events and transient blood count drops.
- Early results from the Phase I/II CASTLE basket trial of zorpocabtagene autoleucel showed 22 of 24 adults with severe autoimmune disease met predefined endpoints with no severe cytokine release syndrome or neurotoxicity.
- Reviews and a new commentary describe in vivo CAR‑T delivery and alternative effector cells as emerging paths that could lower costs and expand access, though they must solve precise targeting, control of persistence, and regulatory oversight.